New York – September 07, 2026 -- Bayesian Health has secured a New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services, making it the first continuous sepsis monitoring technology to hold both FDA clearance and a dedicated Medicare reimbursement pathway.
The approval, issued under CMS's FY 2027 Inpatient Prospective Payment System Final Rule, takes effect October 1, 2026, and allows hospitals using Bayesian's FDA-cleared sepsis flagging device to bill Medicare an add-on payment of up to $61.84 per eligible inpatient case.
NTAP payments will cover an estimated 739 MS-DRGs for three years
The pathway applies to adult Medicare fee-for-service inpatient admissions monitored by Bayesian and spans an estimated 739 Medicare Severity Diagnosis-Related Groups. Because standard hospital payment rates are set on historical claims data that predates new technologies, NTAP provides a temporary add-on to the bundled MS-DRG payment for cases where a qualifying device's costs exceed what that payment covers. The pathway remains active for up to three years.
Sepsis kills 270,000 US hospital patients annually and costs $50 billion
Sepsis drives more than $50 billion in annual US hospital costs, according to figures cited by the company, and each hour of delayed treatment can reduce survival odds by as much as 7.6 percent. Bayesian's CEO, Suchi Saria, said reimbursement removes friction from adoption but is not itself the source of clinical value. "Signal quality clinicians can trust and the end-to-end infrastructure to operationalize those signals into everyday care" is what matters, she said.
Nature Medicine study found 18.2 percent mortality reduction with clinician engagement
The reimbursement decision follows a prospective study published in Nature Medicine, described as one of the largest evaluations of clinical AI conducted to date. Patients whose clinicians engaged with Bayesian's alerts saw an 18.2 percent reduction in mortality and received antibiotics a median of 1.85 hours sooner. The company reports these results have since been matched or exceeded across other health systems, with clinician adoption rates above 80 percent, faster antibiotic delivery, lower resource utilization and reduced sepsis mortality.
Bayesian Health's Chief Medical Officer says hospitals no longer face a financial trade-off
Martin Doerfler, Chief Medical Officer at Bayesian Health, said hospitals "should not have to choose between financial discipline and getting ahead of the deadliest condition facing their patients,